Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a simple screening program stop opioid addiction before it starts?

NCT ID NCT06527599

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study tests a program designed to prevent opioid misuse in people hospitalized for a traumatic injury. Participants complete brief questionnaires about pain and opioid use risk, and receive enhanced care coordination based on their responses. The goal is to see if this adaptive approach is practical and acceptable for patients and staff, paving the way for a larger trial.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Opioid Risk Monitoring and enhanced Trauma Care Coordination
What this could lead to
If successful, this approach could provide a practical, scalable way to identify and support trauma patients at risk for opioid misuse, potentially preventing addiction.
What could go wrong
This is a small pilot study focused on feasibility, not effectiveness. The program may not reduce opioid misuse in a larger, more diverse population.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

118 people

The number who actually took part.

Started

Aug 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Able to speak, read, and write fluently in English. * Admission to site hospital for a traumatic injury at time of screening. A traumatic injury is defined as a physical injury with sudden onset requiring immediate medical attention. * Injury severity score of 9 or greater. * Meets at least one of the following descriptions below: * Received 40 mg morphine milligram equivalent (MME) within 48 hours of pre-screening; or * Discharged with a prescription for an opioid medication. * Expected to be in control of their own medications at the time of discharge from the controlled environment of hospital or short-term rehabilitation. Exclusion Criteria: * Inability to provide written consent for any reason. * Current self-reported diagnosis of cancer with life expectancy less than 12 months at time of screening. * Current prescription for opioid use disorder (e.g., suboxone, buprenorphine, methadone, naltrexone), with a current diagnosis of opioid use disorder (OUD) (mild or greater) not in remission. * History of dementing illnesses and other neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, or vascular dementia. * Current significant traumatic brain injury (defined as the presence of any intracranial blood on Computed Tomography scan of the head or best Glasgow Coma Scale Score of less than 13 at the time of screening). * Current spinal cord injury with persistent neurologic deficit at the time of screening. * Acute stroke immediately prior to/upon admission, or emergent stroke as a new event during hospitalization. * Any vision or hearing impairments resulting in an inability to complete study procedures. * Current pregnancy, as indicated by chart review and self-report. * Involved in any criminal justice proceedings related to illicit substance use at time of screening. * Incarcerated or in police custody at time of study enrollment. * Admitted to the hospital with a burn affecting \>10% total body surface area, as indicated by chart review. * Any medical, physical, cognitive, or psychiatric conditions that would limit the participant's ability to provide informed consent or complete study procedures, as determined by study staff and/or investigators.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Opioid misuse are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Medical College of Wisconsin

    Milwaukee, Wisconsin, 53226, United States

  • UW Health

    Madison, Wisconsin, 53792, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.